CAR-T Pre-Screening in China: What Records Do You Need?
- MedBridgeNZ
- Aug 9
- 14 min read
Updated: 7 days ago
For international patients considering CAR-T pre-screening in China, one of the most useful steps can take place before any flight is booked: preparing a medical record package that allows the receiving specialist or hospital to understand the diagnosis, previous treatments, current disease status and treatment-specific questions.
In this guide, “pre-screening” means preliminary review by the receiving medical institution or specialist. It does not mean medical screening performed by MedBridgeNZ.
A cancer diagnosis alone is rarely enough for a CAR-T team to determine whether further assessment is appropriate. Different CAR-T products and research pathways apply to different diseases, treatment histories and biological targets. The information required for one patient may therefore differ substantially from that required for another.
Key Takeaways
Start with the full disease record, not only a short medical summary. Pathology, imaging, treatment history and recent clinical information may all be relevant.
Keep the original imaging files when possible. A written CT, PET/CT or MRI report may not replace the underlying DICOM images if the receiving team wants to review them.
Record treatment names and dates carefully. Recent chemotherapy, immunotherapy, targeted therapy, steroids or other treatment can create additional questions for the CAR-T team.
A pre-travel record review is not final CAR-T approval. Updated tests, pathology review, imaging or an in-person assessment may still be required by the treating institution.
Quick Answer
Before a Chinese CAR-T center can meaningfully review an international patient’s case, the medical team generally needs enough documentation to understand the diagnosis, treatment history, current disease status and any treatment-specific biomarker or target information.
A practical medical record package may include:
pathology and biopsy reports;
relevant biomarker, immunohistochemistry or flow-cytometry results;
recent CT, PET/CT or MRI reports;
original imaging files when available;
a chronological history of previous cancer treatments;
recent laboratory results already available;
a current medication list;
previous stem cell transplant or CAR-T records, if applicable;
records relating to major medical conditions relevant to treatment planning.
The exact requirements are determined by the receiving CAR-T center and can vary according to the disease, CAR-T product, clinical protocol and the patient’s current condition.
Why Is a Cancer Diagnosis Alone Not Enough for CAR-T Review?
CAR-T is not one treatment with a universal eligibility checklist. Different CAR-T therapies target different antigens and are used in different clinical settings. Some commercially approved products are restricted to particular diseases and previous treatment histories. Other approaches depend on a specific biological target, while some remain available only through clinical research.
For this reason, telling a hospital that someone has “lymphoma,” “multiple myeloma” or “gastric cancer” usually does not provide enough information for a meaningful treatment review.
Definition: CAR-T pre-screening is a preliminary review conducted by the receiving medical institution or specialist before a patient commits to treatment travel.
Function: It helps the medical team understand whether the submitted records support further assessment and what additional information may be required.
Typical Use Case: An international patient wants to determine whether a formal specialist consultation or hospital assessment in China is worth pursuing before arranging international travel.
Why This Matters: An initial review may identify missing pathology, outdated imaging, incomplete treatment history or product-specific questions that should be clarified before the patient travels.
Pre-screening should therefore be understood as a preliminary institutional review, not confirmation that CAR-T treatment will ultimately be offered.
What Medical Records Are Needed for CAR-T Pre-Screening in China?
There is no single record checklist that applies to every CAR-T product, disease or hospital.
However, several categories of information can make it easier for the receiving medical team to reconstruct the case and determine what should happen next.
1. Pathology and the Original Cancer Diagnosis
Begin with the records that establish exactly what disease has been diagnosed.
Depending on the cancer, these may include:
biopsy reports;
surgical pathology reports;
bone marrow pathology;
cytology;
immunohistochemistry;
flow cytometry or immunophenotyping;
molecular or genetic testing already performed.
Whenever more detailed pathology is available, it is usually preferable to include it rather than relying only on a short oncology clinic letter. For CAR-T pathways that depend on a particular cellular target or tumor biomarker, the original pathology and target-testing report may be especially relevant.
International patients who need a broader framework for organizing pathology, imaging, treatment timelines and translations can read our guide on how to prepare medical records for a China specialist review.
2. Biomarker or Target-Expression Results When Relevant
Some CAR-T pathways depend on evidence that the cancer expresses a particular biological target. The relevant target depends entirely on the disease and treatment pathway being considered.
Examples can include targets such as:
CD19 in certain B-cell malignancies;
BCMA in multiple myeloma;
CLDN18.2 in selected gastric or gastroesophageal junction cancer pathways.
These examples are not interchangeable, and not every patient requires the same biomarker testing. The practical principle is:
If a potential CAR-T pathway depends on a specific target, include the original report documenting that target whenever it is available.
A biomarker result should also be interpreted in the context of the diagnosis, previous therapies and current disease status. A positive biomarker alone does not establish CAR-T eligibility.
3. Recent Imaging — Including the Original Scans When Possible
Radiology reports summarize the findings from imaging, but the receiving medical team may also request the original study. Relevant imaging may include:
PET/CT;
contrast-enhanced CT;
MRI;
disease-specific imaging performed during treatment or follow-up.
Whenever possible, patients should retain the original DICOM files rather than screenshots or photographs of scan images. This can matter when the receiving team needs to:
review current disease distribution;
compare scans from different treatment stages;
clarify a reported progression;
assess whether new imaging is required;
arrange an independent radiology review.
Large imaging files often cannot be sent as ordinary email attachments. Secure cloud transfer or another hospital-approved submission method may therefore be required.
In an anonymized MedBridgeNZ gastric cancer inquiry, PDF medical records had already been provided, but the original imaging files still needed to be transferred separately before the case package could be completed for further specialist review.
This is an important distinction:
A radiology report tells the medical team what another radiologist concluded. The original images allow the receiving institution to review the underlying study if it considers that necessary.
4. A Complete Treatment History With Exact Dates
For many CAR-T reviews, treatment chronology is one of the most important parts of the record package.
Instead of writing:
“Several lines of chemotherapy were given.”
prepare a chronological treatment history whenever possible.
Useful details can include:
drug or treatment name;
start date;
end date;
number of cycles;
reason treatment was changed or stopped;
whether progression or response was documented;
major treatment-related complications recorded by the treating team.
Exact dates can become especially important when a patient is still receiving treatment while exploring CAR-T. In one anonymized MedBridgeNZ gastric cancer case, a Chinese specialist requested clarification about the exact start date of a recent systemic therapy and whether subsequent imaging had shown disease progression. The patient then supplied the treatment date and updated progression information before the review continued.
That type of follow-up illustrates why a simple list of drug names may not be enough.
Why Does Recent Treatment Timing Matter?
Recent chemotherapy, immunotherapy, targeted therapy, corticosteroids or other systemic treatment can create questions about:
current disease status;
blood counts and recovery;
timing of further assessment;
potential cell collection;
whether updated testing is required.
The clinical significance of these factors is patient-, product- and institution-specific.
Patients should not stop, postpone or modify cancer treatment based on an online article or while waiting for an overseas consultation. Decisions about ongoing therapy should remain with the patient’s treating oncologist and the relevant CAR-T medical team.
5. Current Medication List
Include medications the patient is taking now, not only anticancer treatment.
Depending on the case, the receiving team may need to know about:
ongoing cancer therapy;
corticosteroids;
anticoagulants;
antimicrobial treatment;
immunosuppressive medication;
cardiac or pulmonary medications;
other clinically significant prescriptions.
Where readily available, include the medication name, dose and relevant treatment dates.
The purpose is not for MedBridgeNZ to interpret these medications. It is to ensure that the receiving medical team has an accurate picture of the patient’s current treatment context.
6. Recent Laboratory and Medical Assessment Records
A CAR-T center may request recent laboratory tests or organ-function assessments as part of its review. The exact tests, acceptable thresholds and required timing can vary between diseases, CAR-T products, research protocols and institutions. For that reason, online articles should not be used as a universal laboratory eligibility checklist. A practical initial submission may include the most recent available:
complete blood count;
chemistry and organ-function tests;
disease-specific laboratory results;
relevant infectious-disease testing already performed;
cardiac or pulmonary assessments when significant comorbidities are documented.
The receiving institution can then specify which investigations need to be repeated or added.
7. Previous CAR-T or Stem Cell Transplant Records
Patients who have already undergone cellular therapy should include as much of the original documentation as possible. Potentially relevant information may include:
previous CAR-T product;
target antigen;
infusion date;
treating institution;
response documented after treatment;
date and pattern of relapse;
significant CAR-T-related complications;
previous autologous or allogeneic stem cell transplantation.
This becomes particularly important when the clinical question involves relapse after an earlier CAR-T treatment.
8. Major Comorbidities and Recent Hospital Admissions
CAR-T treatment decisions are made within the context of the patient’s overall medical condition. Records relating to significant health issues may therefore be relevant, including documented:
heart disease;
chronic lung disease;
renal or liver dysfunction;
neurologic conditions;
active or recent infections;
recent intensive-care admissions;
major gastrointestinal complications;
other clinically significant conditions.
These documents should be available so that the receiving medical team can determine whether further assessment is required. MedBridgeNZ does not make that medical determination.
Are Radiology Reports Enough, or Should You Send the Actual Scans?
When available, it is useful to retain both. The written report and original imaging serve different purposes.
Radiology report
summarizes the local radiologist’s findings;
is easier to review quickly;
helps reconstruct the treatment timeline.
Original imaging
allows another medical team to inspect the study directly if required;
may allow comparisons across treatment stages;
can be important when recent progression or disease burden needs further review.
Patients do not necessarily need to resend every scan they have ever undergone.
A practical starting point is usually the most recent clinically relevant imaging together with earlier imaging that documents an important change in the disease course. The receiving institution can then request additional studies if needed.
Why Should New Medical Information Be Sent Before Travelling?
Cancer status can change while an international consultation or hospital review is being arranged. A new scan, treatment change, infection, hospitalization or significant change in clinical condition may affect the questions the receiving team needs to address.
Patients should therefore avoid assuming that a medical record package submitted several weeks earlier automatically remains current. Examples of updates worth asking the receiving team about include:
new CT, PET/CT or MRI results;
documented disease progression;
a new chemotherapy cycle;
a change in systemic therapy;
a hospital admission;
a significant infection;
major laboratory changes;
newly started medications relevant to treatment planning.
A useful administrative principle is:
If new information has changed the patient’s current oncology care, ask whether the overseas reviewing team also needs the updated record.
MedBridgeNZ can compile, translate and route updated documents. The receiving medical team determines whether those changes affect clinical eligibility or treatment planning.
When Can a Remote CAR-T Record Review Be Useful Before Travel?
Remote record review can be useful when a patient already has a confirmed diagnosis and wants a Chinese specialist or institution to determine whether further CAR-T assessment should be considered before international travel. Depending on the institution, the next step may involve:
preliminary review of submitted records;
a written specialist opinion;
a video consultation;
additional pathology or imaging review;
requests for further medical information;
an in-person assessment in China.
Availability varies by institution and can change according to clinical and administrative scheduling.，Remote review should therefore be understood as a way to clarify the next institutional step, not as a guarantee of treatment acceptance or medical clearance to travel.
A patient who is acutely unwell, requires emergency treatment or needs intensive-care-level support should remain under the direction of the local treating medical team.
Whether a seriously ill patient is medically fit for a long-haul flight is also a clinical decision for the patient’s doctors.
In one anonymized MedBridgeNZ lymphoma case, the Chinese specialist could comment on the potential CAR-T pathway, while the question of fitness for long-haul travel was explicitly left to the patient’s treating physicians at home.
What Administrative Problems Can Make a CAR-T Review More Difficult?
For an international patient, the problem is sometimes not a lack of medical information but the way information is distributed across different hospitals, languages and file formats. Examples include:
treatment dates missing from the summary;
duplicated files with unclear filenames;
scan reports without original images;
imaging files that cannot be opened;
pathology reports separated from biomarker results;
treatment histories spread across several institutions;
medication lists that are no longer current;
untranslated documents;
inconsistent patient names across records;
recent scans or treatment changes that have not been forwarded.
These issues do not determine whether someone is medically eligible for CAR-T.
However, they can make it harder for the receiving institution to reconstruct the case efficiently.
MedBridgeNZ can assist with compiling, formatting, translating and routing medical documentation according to the receiving institution’s stated submission process. Patients who need broader support can review our medical concierge and coordination services for treatment in China. The specialist or hospital remains responsible for all medical interpretation and eligibility decisions.
Self-Arranged vs Administratively Coordinated Record Submission
Pathway/Option | Typical Use Case | Key Considerations |
Self-arranged submission | The patient already has a confirmed hospital contact and an organized record set | The patient manages document preparation, translations, imaging transfer and institutional follow-up |
Administratively coordinated submission | Records are distributed across several providers, languages or file formats | Administrative support can compile, translate, format and route documents without making clinical decisions |
In-person assessment after preliminary review | The receiving institution determines that additional testing or direct examination is required | Travel planning should follow institutional instructions and discussion of travel fitness with the local medical team |
Clinical Case Study
The following is an anonymized MedBridgeNZ case. Identifying and non-essential clinical details have been omitted or generalized to reduce the possibility of re-identification.
Patient Profile
An international patient with advanced gastric cancer contacted MedBridgeNZ to explore whether a biomarker-directed cellular therapy pathway in China warranted specialist review.
The submitted records included pathology and biomarker testing relevant to the treatment pathway, together with previous systemic treatment information and other medical reports.
Initial Recommendation
The first administrative task was to complete the medical record package before further specialist review. Although several PDF records were already available, the original imaging had not yet been transferred. Because the files were too large for ordinary email, they were sent separately. MedBridgeNZ did not determine whether the patient was eligible for CAR-T.
Why a Second Opinion Was Sought
The patient wanted a Chinese oncology specialist to review whether a biomarker-directed cellular therapy pathway might warrant further consideration in the context of disease progression and previous treatment.
This required more than confirmation of the original cancer diagnosis. The specialist needed to consider the relevant pathology and biomarker information together with the treatment history and current disease status.
Multidisciplinary Review
During the later review, the specialist requested clarification about the timing of a recent systemic treatment and whether subsequent imaging showed disease progression. The patient then supplied the requested treatment information and updated imaging findings.
The case demonstrates why biomarker results, original imaging and an accurate treatment timeline should be viewed as connected parts of the same clinical record, rather than as isolated documents.
Outcome
The completed information was subsequently routed through specialist and institutional review channels, with further specialist consultation offered as the next administrative step.
This outcome should not be interpreted as evidence that another patient with similar medical circumstances would receive the same institutional decision.
Please note: Individual medical outcomes vary significantly depending on baseline health, prior treatments, and specific disease progression.
Safety Note
CAR-T is a complex cellular therapy associated with potentially serious adverse effects, which can include cytokine release syndrome, neurologic toxicity and significant blood-count abnormalities. Risks vary between products and patient populations. Treatment risks, current cancer therapy and fitness for CAR-T should be discussed directly with the treating oncologist, hematologist or CAR-T medical team. MedBridgeNZ does not provide medical risk assessment or treatment advice.
Frequently Asked Questions
Can I know if I qualify for CAR-T before flying to China?
A Chinese CAR-T center may be able to conduct a preliminary record review before travel, but this does not guarantee final treatment acceptance. The institution may still require updated laboratory testing, pathology review, imaging, direct examination or other assessments before making a clinical decision.
What medical records do Chinese CAR-T centers usually request before review?
Requirements vary by disease, CAR-T product and institution. A preliminary review commonly starts with pathology, recent imaging, treatment history, current medications and relevant laboratory or biomarker results. The receiving institution should confirm the final document requirements.
Do I need to send the actual PET/CT or CT images?
The receiving hospital may request both the radiology report and the original imaging files.
Original DICOM studies can be useful when the medical team wants to review current disease distribution, compare scans or clarify reported progression.
Do I need biomarker testing before a Chinese CAR-T center reviews my case?
It depends on the pathway being considered. Some CAR-T therapies depend on specific targets such as CD19, BCMA or CLDN18.2, while other products and clinical studies use different disease-specific requirements. Existing biomarker reports should be included when they are relevant, but additional testing should be determined by the treating institution.
Can recent chemotherapy affect a CAR-T record review?
Recent treatment can be relevant to questions involving disease status, laboratory recovery, cell collection and subsequent treatment timing. Patients should provide the exact treatment names and dates to the receiving medical team.
They should not stop or postpone chemotherapy because of information found online. Treatment decisions remain with the treating oncologist and CAR-T team.
Do my medical records need to be translated into Chinese?
Requirements differ between hospitals and consultation pathways. Some international departments may accept English-language documentation, while particular specialists or hospital systems may request Chinese translations. MedBridgeNZ can translate and format medical records according to the stated requirements of the receiving institution.
Can MedBridgeNZ screen me for CAR-T eligibility?
No. MedBridgeNZ does not medically screen patients, diagnose disease or determine whether CAR-T treatment is appropriate. MedBridgeNZ can compile and translate medical records, administratively match an inquiry with specialists or institutions whose published clinical scope is relevant to the case, coordinate record submission and facilitate consultation arrangements. All clinical eligibility and treatment decisions remain with the treating medical team.
Understanding the Pre-Travel Record Pathway
For an international patient, the purpose of preparing records before travel is not to prove that CAR-T treatment will be possible. The goal is to give the receiving institution enough organized information to decide what the next clinical step should be.
1. Initial Case Intake
The patient submits available pathology, imaging reports, treatment history and other relevant medical documentation. MedBridgeNZ can compile, format and translate these records according to the receiving institution’s stated submission requirements.
2. Specialist Matching and Consultation Setup
Based on the documented diagnosis and the patient’s requested consultation question, MedBridgeNZ can administratively match the inquiry with specialists or institutions whose published clinical scope is relevant to the case.
Patients who want broader background information on the types of institutions MedBridgeNZ works with can also review our featured hospital profiles in China.
Where an appropriate institutional pathway is available, MedBridgeNZ can coordinate medical record submission and facilitate the setup of a written or video consultation.
The specialist or institution—not MedBridgeNZ—reviews the clinical information and determines whether additional testing, an in-person assessment or further CAR-T consideration is appropriate.
3. On-the-Ground Coordination
If the institution accepts the case for further assessment and the patient later decides to travel, MedBridgeNZ can coordinate non-clinical arrangements such as hospital registration, bilingual accompaniment, local transport and accommodation. Visa and entry requirements depend on nationality, intended stay and current immigration rules; international patients can review our China medical travel visa guide before making travel arrangements.
Clinical scheduling and treatment timelines remain subject to the receiving institution. Patients who are unsure whether their medical records are ready for institutional submission may contact MedBridgeNZ to discuss medical-record translation, document organization and specialist-liaison pathways.
References
Yakoub-Agha I, et al. Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE). Haematologica. 2020.https://pubmed.ncbi.nlm.nih.gov/31753925/ (PubMed)
Amini L, et al. Preparing for CAR T cell therapy: patient selection, bridging therapies and lymphodepletion. Nature Reviews Clinical Oncology. 2022.https://pubmed.ncbi.nlm.nih.gov/35318469/ (PubMed)
Hayden PJ, et al. Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the EBMT, JACIE and EHA. Annals of Oncology. 2022.https://pubmed.ncbi.nlm.nih.gov/34923107/ (PubMed)
Qi C, et al. Claudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician's choice for previously treated advanced gastric or gastro-oesophageal junction cancer (CT041-ST-01): a randomised, open-label, phase 2 trial. The Lancet. 2025.https://pubmed.ncbi.nlm.nih.gov/40460847/ (PubMed)
National Medical Products Administration of China. Ciltacabtagene Autoleucel Injection Approved for Marketing by China NMPA. 2025.https://english.nmpa.gov.cn/2025-02/19/c_1073591.htm (National Medical Products Administration)
Jiahui Health. International Second Opinions — Medical Record Preparation, Telepathology, Teleradiology and Remote Consultation.https://www.jiahui.com/en/service/90
Jiahui International Cancer Center. World’s First International Patient Starts Newly Approved Solid Tumor CAR-T. 2026.https://jicc.jiahui.com/en_US/news/217 (Jiahui International Oncology Center)
Santomasso BD, et al. Management of Immune-Related Adverse Events in Patients Treated With Chimeric Antigen Receptor T-Cell Therapy: ASCO Guideline. Journal of Clinical Oncology. 2021.https://pubmed.ncbi.nlm.nih.gov/34724386/ (PubMed)
Disclaimer: MedBridgeNZ acts strictly as an international medical concierge and logistics coordinator. We do not provide direct medical treatment, diagnosis, or clinical advice. This content is for informational purposes only and does not constitute medical guidance. Always consult your primary physician or treating oncologist before pursuing cross-border treatment options.
